Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

被引:324
|
作者
Eich, Hans Theodor
Diehl, Volker
Goergen, Helen
Pabst, Thomas
Markova, Jana
Debus, Juergen
Ho, Anthony
Doerken, Bernd
Rank, Andreas
Grosu, Anca-Ligia
Wiegel, Thomas
Karstens, Johann Hinrich
Greil, Richard
Willich, Normann
Schmidberger, Heinz
Doehner, Hartmut
Borchmann, Peter
Mueller-Hermelink, Hans-Konrad
Mueller, Rolf-Peter
Engert, Andreas [1 ]
机构
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
关键词
POSITRON-EMISSION-TOMOGRAPHY; INTERNATIONAL PROGNOSTIC SCORE; NODE RADIOTHERAPY; STAGE-I; DISEASE; CYCLES; PROGRESSION; RADIATION; SUPERIOR; THERAPY;
D O I
10.1200/JCO.2010.29.8018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Combined-modality treatment consisting of four to six cycles of chemotherapy followed by involved-field radiotherapy (IFRT) is the standard of care for patients with early unfavorable Hodgkin's lymphoma (HL). It is unclear whether treatment results can be improved with more intensive chemotherapy and which radiation dose needs to be applied. Patients and Methods Patients age 16 to 75 years with newly diagnosed early unfavorable HL were randomly assigned in a 2 x 2 factorial design to one of the following treatment arms: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy of IFRT; four cycles of ABVD + 20 Gy of IFRT; four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP(baseline)) + 30 Gy of IFRT; or four cycles of BEACOPP(baseline) + 20 Gy of IFRT. Results With a total of 1,395 patients included, the freedom from treatment failure (FFTF) at 5 years was 85.0%, overall survival was 94.5%, and progression-free survival was 86.0%. BEACOPP(baseline) was more effective than ABVD when followed by 20 Gy of IFRT (5-year FFTF difference, 5.7%; 95% CI, 0.1% to 11.3%). However, there was no difference between BEACOPP(baseline) and ABVD when followed by 30 Gy of IFRT (5-year FFTF difference, 1.6%; 95% CI, -3.6% to 6.9%). Similar results were observed for the radiotherapy question; after four cycles of BEACOPP(baseline), 20 Gy was not inferior to 30 Gy (5-year FFTF difference, -0.8%; 95% CI, -5.8% to 4.2%), whereas inferiority of 20 Gy cannot be excluded after four cycles of ABVD (5-year FFTF difference, -4.7%; 95% CI, -10.3% to 0.8%). Treatment-related toxicity occurred more often in the arms with more intensive therapy. Conclusion Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL. Four cycles of ABVD should be followed by 30 Gy of IFRT.
引用
收藏
页码:4199 / 4206
页数:8
相关论文
共 50 条
  • [21] Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma
    Luthy, S. K.
    Ng, A. K.
    Silver, B.
    Degnan, K. O.
    Fisher, D. C.
    Freedman, A. S.
    Mauch, P. M.
    ANNALS OF ONCOLOGY, 2008, 19 (12) : 2043 - 2047
  • [22] Feasibility and Efficacy of ABVD In Elderly Hodgkin Lymphoma Patients: Analysis of Two Randomized Prospective Multicenter Trials of the German Hodgkin Study Group (HD10 and HD11)
    Boll, Boris
    Gorgen, Helen
    Fuchs, Michael
    von Tresckow, Bastian
    Engert, Andreas
    Borchmann, Peter
    BLOOD, 2010, 116 (21) : 186 - 187
  • [23] Quality control of involved-field radiotherapy for patients with early stage Hodgkin's lymphoma based on a central prospective review Comparison of the results between two study generations of the German Hodgkin Study Group
    Kriz, J.
    Bangard, C.
    Haverkamp, U.
    Bongartz, R.
    Baues, C.
    Engert, A.
    Mueller, R-P
    Eich, H. T.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (08) : 660 - 665
  • [24] Dose-Escalation with BEACOPP Escalated Is Superior to ABVD In the Combined-Modality Treatment of Early Unfavorable Hodgkin Lymphoma: Final Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial
    Engert, Andreas
    Borchmann, Peter
    Pluetschow, Annette
    von Tresckow, Bastian
    Markova, Jana
    Hitz, Felicitas
    Kral, Zdenek
    Greil, Richard
    Topp, Max S.
    Villalobos, Matthias
    Zijlstra, Josee M.
    Soekler, Martin
    Stein, Harald
    Eich, Hans-Theodor
    Mueller, Rolf-Peter
    Fuchs, Michael
    Diehl, Volker
    BLOOD, 2010, 116 (21) : 336 - 336
  • [25] FEASIBILITY AND EFFICACY OF ABVD IN ELDERLY HODGKIN LYMPHOMA PATIENTS: ANALYSIS OF TWO RANDOMIZED PROSPECTIVE MULTICENTER TRIALS OF THE GERMAN HODGKIN STUDY GROUP (HD10 AND HD11)
    Boell, B.
    Goergen, H.
    Fuchs, M.
    von Tresckow, B.
    Engert, A.
    Borchmann, P.
    HAEMATOLOGICA, 2010, 95 : S39 - S39
  • [26] Dose-Intensification in Early Unfavorable Hodgkin Lymphoma: Long-Term Follow up of the German Hodgkin Study Group (GHSG) HD14 Trial
    Gillessen, Sarah
    Plutschow, Annette
    Fuchs, Michael
    Markova, Jana
    Greil, Richard
    Topp, Max S.
    Meissner, Julia
    Zijlstra, Josee M.
    Eichenauer, Dennis A.
    Diehl, Volker
    Borchmann, Peter
    Engert, Andreas
    von Tresckow, Bastian
    BLOOD, 2019, 134
  • [27] DOSE-ESCALATION WITH BEACOPP ESCALATED IS SUPERIOR TO ABVD IN THE COMBINED-MODALITY TREATMENT OF EARLY UNFAVORABLE HODGKIN LYMPHOMA (HL): FINAL ANALYSIS OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD14 TRIAL
    Borchmann, P.
    Diehl, V.
    Pluetschow, A.
    Von Tresckow, B.
    Markova, J.
    Hitz, F.
    Kra, Z.
    Greil, R.
    Topp, M. S.
    Villalobos, M.
    Zijlstra, J. M.
    Soekler, M.
    Fuchs, M.
    Engert, A.
    ANNALS OF ONCOLOGY, 2011, 22 : 180 - 180
  • [28] Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group
    Borchmann, P.
    Kobe, C.
    Pluetschow, A.
    Greil, R.
    Meissner, J.
    Topp, M. S.
    Ostermann, H.
    Dierlamm, J.
    Mohm, J.
    Thiemer, J.
    Soekler, M.
    Kerkhoff, A.
    Ahlborn, M.
    Halbsguth, T.
    Martin, S.
    Keller, U.
    Balabanov, S.
    Pabst, T.
    Vogelhuber, M.
    Huettmann, A.
    Wilhem, M.
    Zijlstra, J. M.
    Moccia, A.
    Broeckelmann, P. J.
    von Tresckow, B.
    Fuchs, M.
    Eich, H.
    Baues, C.
    Hallek, M.
    Diehl, V
    Dietlein, M.
    Engert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 32 - 32
  • [29] Two Cycles of ABVD Followed by Involved Field Radiotherapy with 20 Gray (Gy) is the New Standard of Care in the Treatment of Patients with Early Stage Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group (GHSG) Trial HD10
    Mueller, R. P.
    Eich, H. T.
    Pluetschow, A.
    Debus, J.
    Bamberg, M.
    Wilbom, K.
    Eble, M.
    Mueller-Hennelink, H.
    Diehl, V.
    Engert, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S26 - S27